Head-to-Head trial tests new hope for Muscle-Weakening disease
NCT ID NCT07217587
Summary
This study compares two experimental drugs, nipocalimab and efgartigimod, for adults with generalized myasthenia gravis—an autoimmune disease that causes severe muscle weakness. Researchers want to see which drug better reduces harmful antibodies and improves daily activities like talking, chewing, and breathing. The trial also tests if patients already on efgartigimod can safely switch to nipocalimab for better or longer-lasting symptom control.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYASTHENIA GRAVIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Atrium Health Wake Forest Baptist
RECRUITINGWinston-Salem, North Carolina, 27157, United States
-
HSHS St. Elizabeth's Hospital
RECRUITINGO'Fallon, Illinois, 62269, United States
-
Henry Ford Hospital
RECRUITINGDetroit, Michigan, 48202, United States
-
Rambam Medical Center
RECRUITINGHaifa, 3109601, Israel
-
SFM Clinical Research LLC
RECRUITINGBoca Raton, Florida, 33487, United States
-
Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
-
University of Connecticut
RECRUITINGFarmington, Connecticut, 06030, United States
Conditions
Explore the condition pages connected to this study.